Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Coya Therapeutics, Inc. - Common Stock
(NQ:
COYA
)
6.790
+0.290 (+4.46%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
37,810
Open
6.610
Bid (Size)
6.500 (1)
Ask (Size)
9.000 (2)
Prev. Close
6.500
Today's Range
6.510 - 7.200
52wk Range
3.210 - 10.69
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic
June 20, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology
June 11, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Performance
YTD
-2.44%
-2.44%
1 Month
-4.37%
-4.37%
3 Month
-29.56%
-29.56%
6 Month
-2.86%
-2.86%
1 Year
+65.01%
+65.01%
More News
Read More
Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology
June 03, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
COYA Stock Earnings: Coya Therapeutics Reported Results for Q4 2023
March 19, 2024
Via
InvestorPlace
Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index
May 28, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
7 Biotech Stocks to Put on Your Breakthrough Radar
May 27, 2024
Via
InvestorPlace
EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases
May 27, 2024
Via
Benzinga
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease
May 22, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics
February 29, 2024
Via
Talk Markets
Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)
May 20, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
COYA Stock Earnings: Coya Therapeutics Misses EPS for Q1 2024
May 09, 2024
Via
InvestorPlace
Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results
May 09, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
April 26, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics to Participate in the Mizuho Neuroscience Summit
April 22, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
April 18, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
April 08, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
March 19, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics to Participate in BTIG Fireside Discussion
March 12, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference
March 12, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference
March 06, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference
February 29, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology Conference
February 22, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a “Pipeline in a Product”
February 21, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases
February 13, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Secures Key Financing In Its Fight Against Myriad Diseases
February 05, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.